Skip to main content
Top
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?

Authors: Sérgia Velho, Cátia Moutinho, Luís Cirnes, Cristina Albuquerque, Richard Hamelin, Fernando Schmitt, Fátima Carneiro, Carla Oliveira, Raquel Seruca

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

BRAF, KRAS and PIK3CA mutations are frequently found in sporadic colorectal cancer (CRC). In contrast to KRAS and PIK3CA mutations, BRAF mutations are associated with tumours harbouring CpG Island methylation phenotype (CIMP), MLH1 methylation and microsatellite instability (MSI). We aimed at determine the frequency of KRAS, BRAF and PIK3CA mutations in the process of colorectal tumourigenesis using a series of colorectal polyps and carcinomas. In the series of polyps CIMP, MLH1 methylation and MSI were also studied.

Methods

Mutation analyses were performed by PCR/sequencing. Bisulfite treated DNA was used to study CIMP and MLH1 methylation. MSI was detected by pentaplex PCR and Genescan analysis of quasimonomorphic mononucleotide repeats. Chi Square test and Fisher's Exact test were used to perform association studies.

Results

KRAS, PIK3CA or BRAF occur in 71% of polyps and were mutually exclusive. KRAS mutations occur in 35% of polyps. PIK3CA was found in one of the polyps. V600E BRAF mutations occur in 29% of cases, all of them classified as serrated adenoma. CIMP phenotype occurred in 25% of the polyps and all were mutated for BRAF. MLH1 methylation was not detected and all the polyps were microsatellite stable. The comparison between the frequency of oncogenic mutations in polyps and CRC (MSI and MSS) lead us to demonstrate that KRAS and PIK3CA are likely to precede both types of CRC. BRAF mutations are likely to precede MSI carcinomas since the frequency found in serrated polyps is similar to what is found in MSI CRC (P = 0.9112), but statistically different from what is found in microsatellite stable (MSS) tumours (P = 0.0191).

Conclusion

Our results show that BRAF, KRAS and PIK3CA mutations occur prior to malignant transformation demonstrating that these oncogenic alterations are primary genetic events in colorectal carcinogenesis. Further, we show that BRAF mutations occur in association with CIMP phenotype in colorectal serrated polyps and verified that colorectal serrated polyps and MSI CRC show a similar frequency of BRAF mutations. These results support that BRAF mutations harbour a mild oncogenic effect in comparison to KRAS and suggest that BRAF mutant colorectal cells need to accumulate extra epigenetic alterations in order to acquire full transformation and evolve to MSI CRC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ionov Y, Peinado M, Malkhosyan S, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993, 363 (6429): 558-561. 10.1038/363558a0.CrossRefPubMed Ionov Y, Peinado M, Malkhosyan S, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993, 363 (6429): 558-561. 10.1038/363558a0.CrossRefPubMed
2.
go back to reference Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J, Jungling B, Zeuzem S, Raedle J: BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer. 2005, 104 (5): 952-961. 10.1002/cncr.21266.CrossRefPubMed Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J, Jungling B, Zeuzem S, Raedle J: BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer. 2005, 104 (5): 952-961. 10.1002/cncr.21266.CrossRefPubMed
3.
go back to reference Domingo E, Espín E, Armengol M, Oliveira C, Pinto M, Duval A, Brennetot C, Seruca R, Hamelin R, Yamamoto H, Schwartz SJ: Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer. 2004, 39 (2): 138-142. 10.1002/gcc.10310.CrossRefPubMed Domingo E, Espín E, Armengol M, Oliveira C, Pinto M, Duval A, Brennetot C, Seruca R, Hamelin R, Yamamoto H, Schwartz SJ: Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer. 2004, 39 (2): 138-142. 10.1002/gcc.10310.CrossRefPubMed
4.
go back to reference Weisenberger D, Siegmund K, Campan M, Young J, Long T, Faasse M, Kang G, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French A, Thibodeau S, Jass J, Haile R, Laird P: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006, 38 (7): 787-793. 10.1038/ng1834.CrossRefPubMed Weisenberger D, Siegmund K, Campan M, Young J, Long T, Faasse M, Kang G, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French A, Thibodeau S, Jass J, Haile R, Laird P: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006, 38 (7): 787-793. 10.1038/ng1834.CrossRefPubMed
5.
go back to reference Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, Capelinha A, Duval A, Hamelin R, Machado J, Schwartz SJ, Carneiro F, Seruca R: KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007, 26 (1): 158-163. 10.1038/sj.onc.1209758.CrossRefPubMed Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, Capelinha A, Duval A, Hamelin R, Machado J, Schwartz SJ, Carneiro F, Seruca R: KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007, 26 (1): 158-163. 10.1038/sj.onc.1209758.CrossRefPubMed
6.
go back to reference Oliveira C, Westra J, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira M, Ligtenberg M, Kleibeuker J, Sijmons R, Plukker J, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz SJ, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen L, Seruca R, Hofstra R: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet. 2004, 13 (19): 2303-2311. 10.1093/hmg/ddh238.CrossRefPubMed Oliveira C, Westra J, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira M, Ligtenberg M, Kleibeuker J, Sijmons R, Plukker J, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz SJ, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen L, Seruca R, Hofstra R: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet. 2004, 13 (19): 2303-2311. 10.1093/hmg/ddh238.CrossRefPubMed
7.
go back to reference Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. 2003, 22 (57): 9192-9196. 10.1038/sj.onc.1207061.CrossRefPubMed Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. 2003, 22 (57): 9192-9196. 10.1038/sj.onc.1207061.CrossRefPubMed
8.
go back to reference Samowitz W, Albertsen H, Herrick J, Levin T, Sweeney C, Murtaugh M, Wolff R, Slattery M: Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005, 129 (3): 837-845. 10.1053/j.gastro.2005.06.020.CrossRefPubMed Samowitz W, Albertsen H, Herrick J, Levin T, Sweeney C, Murtaugh M, Wolff R, Slattery M: Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005, 129 (3): 837-845. 10.1053/j.gastro.2005.06.020.CrossRefPubMed
9.
go back to reference Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell S, Riggins G, Willson J, Markowitz S, Kinzler K, Vogelstein B, Velculescu V: High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304 (5670): 554-10.1126/science.1096502.CrossRefPubMed Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell S, Riggins G, Willson J, Markowitz S, Kinzler K, Vogelstein B, Velculescu V: High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304 (5670): 554-10.1126/science.1096502.CrossRefPubMed
10.
go back to reference Velho S, Oliveira C, Ferreira A, Ferreira A, Suriano G, Schwartz SJ, Duval A, Carneiro F, Machado J, Hamelin R, Seruca R: The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005, 41 (11): 1649-1654. 10.1016/j.ejca.2005.04.022.CrossRefPubMed Velho S, Oliveira C, Ferreira A, Ferreira A, Suriano G, Schwartz SJ, Duval A, Carneiro F, Machado J, Hamelin R, Seruca R: The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005, 41 (11): 1649-1654. 10.1016/j.ejca.2005.04.022.CrossRefPubMed
11.
go back to reference Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R: Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002, 123 (6): 1804-1811. 10.1053/gast.2002.37070.CrossRefPubMed Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R: Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002, 123 (6): 1804-1811. 10.1053/gast.2002.37070.CrossRefPubMed
12.
go back to reference Wynter C, Walsh M, Higuchi T, Leggett B, Young J, Jass J: Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut. 2004, 53 (4): 573-580. 10.1136/gut.2003.030841.CrossRefPubMedPubMedCentral Wynter C, Walsh M, Higuchi T, Leggett B, Young J, Jass J: Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut. 2004, 53 (4): 573-580. 10.1136/gut.2003.030841.CrossRefPubMedPubMedCentral
13.
go back to reference O'Brien M: Hyperplastic and serrated polyps of the colorectum. Gastroenterol Clin North Am. 2007, 36 (4): 947-968. 10.1016/j.gtc.2007.08.007.CrossRefPubMed O'Brien M: Hyperplastic and serrated polyps of the colorectum. Gastroenterol Clin North Am. 2007, 36 (4): 947-968. 10.1016/j.gtc.2007.08.007.CrossRefPubMed
14.
go back to reference O'Brien M, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, Amorosino M, Farraye F: Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol. 2006, 30 (12): 1491-1501. 10.1097/01.pas.0000213313.36306.85.CrossRefPubMed O'Brien M, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, Amorosino M, Farraye F: Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol. 2006, 30 (12): 1491-1501. 10.1097/01.pas.0000213313.36306.85.CrossRefPubMed
15.
go back to reference Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M, Nakamura Y, White R, Smits A, Bos J: Genetic alterations during colorectal-tumor development. N Engl J Med. 319 (9): 525-532. 1988, Sep 1 Vogelstein B, Fearon E, Hamilton S, Kern S, Preisinger A, Leppert M, Nakamura Y, White R, Smits A, Bos J: Genetic alterations during colorectal-tumor development. N Engl J Med. 319 (9): 525-532. 1988, Sep 1
16.
go back to reference Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M: A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 2007, 21 (4): 379-384. 10.1101/gad.1516407.CrossRefPubMedPubMedCentral Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M: A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 2007, 21 (4): 379-384. 10.1101/gad.1516407.CrossRefPubMedPubMedCentral
17.
go back to reference Wajapeyee N, Serra R, Zhu X, Mahalingam M, Green M: Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7. Cell. 2008, 132: 363-374. 10.1016/j.cell.2007.12.032.CrossRefPubMedPubMedCentral Wajapeyee N, Serra R, Zhu X, Mahalingam M, Green M: Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7. Cell. 2008, 132: 363-374. 10.1016/j.cell.2007.12.032.CrossRefPubMedPubMedCentral
18.
go back to reference Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, Horst Cvd, Majoor D, Shay J, Mooi W, Peeper D: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005, 436 (7051): 720-724. 10.1038/nature03890.CrossRefPubMed Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, Horst Cvd, Majoor D, Shay J, Mooi W, Peeper D: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005, 436 (7051): 720-724. 10.1038/nature03890.CrossRefPubMed
19.
go back to reference Jass J: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007, 50 (1): 113-130. 10.1111/j.1365-2559.2006.02549.x.CrossRefPubMed Jass J: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007, 50 (1): 113-130. 10.1111/j.1365-2559.2006.02549.x.CrossRefPubMed
20.
21.
go back to reference Minoo P, Moyer M, Jass J: Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol. 2007, 212 (2): 124-133. 10.1002/path.2160.CrossRefPubMed Minoo P, Moyer M, Jass J: Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol. 2007, 212 (2): 124-133. 10.1002/path.2160.CrossRefPubMed
22.
go back to reference Kambara T, Simms L, Whitehall V, Spring K, Wynter C, Walsh M, Barker M, Arnold S, McGivern A, Matsubara N, Tanaka N, Higuchi T, Young J, Jass J, Leggett B: BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004, 53 (8): 1137-1144. 10.1136/gut.2003.037671.CrossRefPubMedPubMedCentral Kambara T, Simms L, Whitehall V, Spring K, Wynter C, Walsh M, Barker M, Arnold S, McGivern A, Matsubara N, Tanaka N, Higuchi T, Young J, Jass J, Leggett B: BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004, 53 (8): 1137-1144. 10.1136/gut.2003.037671.CrossRefPubMedPubMedCentral
23.
go back to reference Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez N, Chen X, Ahmed S, Konishi K, Hamilton S, Issa J: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 104 (47): 18654-18659. 10.1073/pnas.0704652104. 2007, Nov 20; Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez N, Chen X, Ahmed S, Konishi K, Hamilton S, Issa J: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 104 (47): 18654-18659. 10.1073/pnas.0704652104. 2007, Nov 20;
24.
go back to reference Sawyer E, Cerar A, Hanby A, Gorman P, Arends M, Talbot I, Tomlinson I: Molecular characteristics of serrated adenomas of the colorectum. Gut. 2002, 51 (2): 200-206. 10.1136/gut.51.2.200.CrossRefPubMedPubMedCentral Sawyer E, Cerar A, Hanby A, Gorman P, Arends M, Talbot I, Tomlinson I: Molecular characteristics of serrated adenomas of the colorectum. Gut. 2002, 51 (2): 200-206. 10.1136/gut.51.2.200.CrossRefPubMedPubMedCentral
Metadata
Title
BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?
Authors
Sérgia Velho
Cátia Moutinho
Luís Cirnes
Cristina Albuquerque
Richard Hamelin
Fernando Schmitt
Fátima Carneiro
Carla Oliveira
Raquel Seruca
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-255

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine